临床研究中的统计学争议:肿瘤学无效性分析——一项随机对照试验的潜在陷阱教训
LUME-Lung 2研究因预设的非结合性无效性分析(基于研究者评估的无进展生存期PFS)提前终止,但最终分析显示中心评估的PFS主要终点达标。回顾性分析显示,预设无效性分析时条件功效为10.3%、预测功效为18.5%,条件与预测功效随时间波动,仅在无效性分析时点降至阈值以下。作者认为无效性分析设计需审慎考虑,二次分析确认无效性结果可能合适。
要点
- 预设无效性分析时条件功效10.3%、预测功效18.5%,未见安全性问题。
- 回顾性分析显示条件与预测功效随时间波动,仅在无效性分析时点降至阈值以下。
- 作者认为无效性分析设计需审慎考虑,二次分析确认无效性结果可能合适。
核心结论
- 回顾性研究提示,若数据监查委员会(DMC)分析在其他时间点进行或采用中心评估的PFS数据,无效性结果可能不同,试验可能继续。
- 无效性分析的设计需审慎考虑,二次分析确认无效性结果可能合适。
研究设计与样本
- LUME-Lung 2研究(NCT00806819;1199.14)为随机对照试验,比较尼达尼布联合培美曲塞与安慰剂联合培美曲塞治疗晚期或复发性非鳞状非小细胞肺癌,患者为一线化疗后复发或失败者。
- 预设无效性分析由数据监查委员会(DMC)在主要PFS分析事件数达到50%(713事件)后进行,无效性阈值为条件功效<20%。
- 回顾性分析在研究者评估和中心评估的PFS不同事件百分比发生后计算条件/预测功效和风险比。
主要发现
- 预设无效性分析时,条件功效为10.3%,预测功效为18.5%,未发现安全性问题。
- 回顾性分析显示,研究者评估和中心评估的PFS的条件与预测功效随时间波动,仅在无效性分析时点功效显著下降并低于无效性阈值。
关键数值与推荐
- 预设无效性分析阈值:条件功效<20%。
- 预设无效性分析时条件功效10.3%,预测功效18.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-planned futility analyses are commonly used in oncology studies. The LUME-Lung 2 study (NCT00806819; 1199.14) was stopped early based on a pre-planned, non-binding futility analysis of investigator-assessed progression-free survival (PFS), although subsequent analysis showed that the primary endpoint of improvement in centrally reviewed PFS was met. Retrospective analyses were conducted to understand the discrepancy between interim futility and final analyses. MATERIALS AND METHODS: LUME-Lung 2 investigated nintedanib in combination with pemetrexed versus placebo‒pemetrexed for the treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer who had relapsed or failed one prior line of chemotherapy. Pre-planned futility analysis was carried out by the Data Monitoring Committee (DMC) after 50% of the events for the primary PFS analysis (713 events) had occurred; the threshold for futility was a conditional power of < 20%. Conditional/predictive powers and hazard ratios were calculated retrospectively after varying percentages of events had occurred for both investigator- and centrally reviewed PFS. RESULTS: At the time of the pre-planned futility analysis, the conditional power was 10.3% and the predictive power was 18.5%; no safety issues were identified. Retrospective analysis showed that the conditional and predictive powers fluctuated considerably over time for both investigator- and centrally reviewed PFS and that the power only dropped by a notable amount, and below the futility threshold, at the time of the futility analysis. CONCLUSIONS: Retrospective investigations suggest that, had the DMC analysis been carried out at another time point, or had centrally reviewed PFS data been used, the futility outcome may have been different and the trial may have been continued. The design of futility analyses requires careful consideration and confirming negative futility outcomes by second analysis may be appropriate. TRIAL NUMBER: NCT00806819.
引用
- Lesaffre E, Edelman MJ, Hanna NH, et al. Statistical controversies in clinical research: futility analyses in oncology-lessons on potential pitfalls from a randomized controlled trial. Ann Oncol. 2017. PMID: 28184431. doi:10.1093/annonc/mdx042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。